title: Pharmacological classification of central post-stroke pain: comparison with the results of chronic motor cortex stimulation therapy.
abstract: In an attempt to clarify the neurochemical background of central post-stroke pain and to undertake a pharmacological analysis, the basic pharmacological characteristics of this intractable pain syndrome were investigated by the morphine, thiamylal and ketamine tests. In addition, the correlation between the pharmacological characteristics and the effects of chronic motor cortex stimulation therapy was examined. The study employed 39 central post-stroke pain patients who had intractable hemibody pain associated with dysesthesias, and radiologically demonstrated lesions in the thalamic area (thalamic pain, n = 25) or suprathalamic area (suprathalamic pain, n = 14). The pharmacological evaluations showed that definite pain reduction occurred in eight of the 39 cases (20.5%) by the morphine test, in 22 of the 39 cases (56.4%) by the thiamylal test, and in 11 of 23 cases (47.8%) by the ketamine test. Based on these pharmacological assessments, there was no obvious difference between thalamic and suprathalamic pain. A comparison of the long-term follow-up results of chronic motor cortex stimulation therapy revealed that thiamylal and ketamine-sensitive and morphine-resistant cases displayed long-lasting pain reduction with chronic motor cortex stimulation therapy, whereas the remaining cases did not show good results. We conclude that pharmacological classification of central post-stroke pain by the morphine, thiamylal and ketamine tests could be useful for predicting the effects of chronic motor cortex stimulation therapy. It has recently been suggested that excitatory amino acids may be involved in the development of central post-stroke pain. However, the fact that only 23 of the present 39 cases (59.0%) of thalamic and suprathalamic pain were sensitive to the thiamylal or ketamine test reflects the complex pharmacological background and the difficulties associated with treating central post-stroke pain.
authors.affiliation: Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Katayama
authors.forename: T
authors.initials: T
authors.lastname: Hirayama
authors.forename: T
authors.initials: T
authors.lastname: Tsubokawa
mesh_terms: D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid; D000777:Anesthetics; D002561:Cerebrovascular Disorders / Q000150:complications*; D005260:Female; D006801:Humans; D007649:Ketamine; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009020:Morphine; D009044:Motor Cortex / Q000187:drug effects*; D010146:Pain / Q000188:drug therapy*; D013268:Stimulation, Chemical; D013577:Syndrome; D013788:Thalamus / Q000187:drug effects*; D013840:Thiamylal
chemical_list: D000701:Analgesics, Opioid; D000777:Anesthetics; D013840:Thiamylal; D007649:Ketamine; D009020:Morphine